Credit Designation Statement

The AOFAS designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.

AOFAS requires all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all relevant financial relationships or affiliations during the past 12 months with any commercial interest (any entity producing, marketing, re-selling, or distributing healthcare goods and services consumed by, or used on patients). All identified conflicts of interest must be resolved and the education content vetted by AOFAS for fair balance, scientific objectivity, and appropriateness. AOFAS also requires faculty to disclose when off-label/unapproved uses of a product are discussed in a CME activity. AOFAS attests that the persons responsible for the development of this educational activity did so independently and were not influenced by commercial supporters. All financial disclosures will be provided to meeting attendees in the final program materials.

The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.

FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.

Disclosure Statement

AOFAS mandates all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients

All identified conflicts must be mitigated, and the education content vetted by the AOFAS for fair balance, scientific objectivity, and appropriateness. All disclosures will be provided in this final program distributed at the meeting to all program participants.

FDA Statement

Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration

As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:

Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty

members are required to ensure that all material presented and discussed will be based on best- available evidence.

Webinar Faculty Disclosures

Paul Talusan, MD

Paragon28, Inc.: Grant/Research Support, Paid Consultant

James Holmes, MD

Nothing to Disclose

Christopher Miller, MD

Arthrex, Inc: Grant/Research Support, Paid Consultant, Speakers' Bureau

Kaitlin Neary, MD

Arthrex: Paid Consultant

EDUCATION COMMITTEE DISCLOSURES (Planners)

Mike Aronow, MD

AAOS: Board Member/Committee Member

American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

Connecticut Orthopaedic Society: Board Member/Committee Member

CreOsso, LLC: Stock or stock options

Techniques in Foot and Ankle Surgery: Editorial/Governing board - Publications

Jonathon D. Backus, MD

American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

Marrow Access Technologies: Stock or Stock Options

Medline Unite: Paid Consultant, Royalties - Publisher

Callum Clark, MD

Arthrex Inc.: Speakers' Bureau

M. Truitt Cooper, MD

GLW: Stock-privately held company

In2Bones: Paid Consultant, Royalties

Smith & Nephew: Grant/Research Support

Stryker: Educational Grant

Canon Cornelius, MD

This individual reported nothing to disclose

Cesar de Cesar Netto, MD

AAOS: Board Member/Committee Member

AOFAS: Board Member/Committee Member

Artelon: Paid Consultant, Royalties

CurveBeam: Paid Consultant, Stock or stock options

Foot & Ankle International: Editorial/Governing board – Publications

Foot and Ankle Clinics: Editorial/Governing board - Publications

International WBCT Society: Board member/Committee Member

Medartis: Paid Consultant, Royalties

Paragon 28: Grant/Research Support, Paid Consultant, Royalties

Stryker: Paid Consultant

Tayco Brace: Stock-privately held company

Zimmer-Biomet: Paid Consultant, Royalties

Daniel C Farber, MD

JMEA: Stock-privately held company

Treace Medical Concepts, Inc.: Paid Consultant

Alena Frey

Staff

This individual reported nothing to disclose

Lauren Geaney, MD

American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

CT Othopedic Society: Board Member/Committee Member

FAI: Editorial/Governing board – Publications

Novastep: Paid Consultant

Paragon 28: Paid consultant, Royalties

Smith & Nephew: Paid consultant

Vilex: Paid consultant

Julie Glosson

Staff

This individual reported nothing to disclose

Daniel Guss, MD

AOFAS: Board Member/Committee Member

Butterfly, Inc.: Grant/Research Support

Ossio: Paid Consultant, Stock-privately held company

Paragon 28: Fellowship Support

Amgad M. Haleem Amin, MD

Vilex, LLC: Paid Consultant

Wright/Stryker medical: Paid Consultant

Tracy Harig, MD

This individual reported nothing to disclose

Jeannie Huh, MD

This individual reported nothing to disclose

Kenneth Hunt, MD

JISAKOS: Editorial/Governing board – Publications

Panther Orthopaedics: Stock-privately held company

Paragon 28: Editorial/Governing board – Publications, Paid Consultant

Kelly K. Hynes, MD

  Acumed LLC: Paid Consultant

  American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

  Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member

  Endo Pharmaceuticals Inc: Paid Consultant

  Ortho Xcel: Paid Consultant

Brandon King, MD

Heron Therapeutics: Paid Consultant

Ashlee MacDonald, MD

 This individual reported nothing to disclose

Elizabeth Martin, MD

American Orthopaedic Foot and Ankle Society: Board Member/Committee Member

Max Michalski, MD

Arthrex Inc.: Grant/Research Support

Extremity Medical: Paid Consultant, Royalties, Speakers' Bureau

Mohamed Mokhtar Abd-Ella, MD

This individual reported nothing to disclose

Jennifer Moore

Staff

This individual reported nothing to disclose

Irvin Oh, MD

Innomed: Royalties

Joseph O’Neil, MD

This individual reported nothing to disclose

Christian A. Ortiz, MD

ACUMED.: Paid Consultant

AO: Board member/Committee Member

Charles Saltzman, MD

Lima: Unpaid Consultant

Nextremity Solutions: Paid Consultant

Paragon28, Inc.: Paid Consultant

Saunders/Mosby-Elsevier: Royalties – Publisher

Vilex, LLC: Paid Consultant

Zimmer Biomet: Royalties - Publisher

Glenn Shi, MD

This individual reported nothing to disclose

Monica Volesky, MD

Arthrex: Speakers' Bureau

Canadian Orthopaedic Foot and Ankle Society: Board Member/Committee Member

Wright Medical: Other Financial or Material Support

Richard Zell, MD

   This individual reported nothing to disclose

Jacob Rothschild Zide, MD

Orthofix: Paid consultant

All of the relevant financial relationships listed for these individuals have been mitigated.

Paul Talusan, MD is an Associate Professor of Orthopaedic Surgery at the University of Michigan specializing in disorders of the Foot and Ankle. Dr. Talusan was raised in Boston, where he completed his undergraduate studies at Boston College. He was awarded a medical degree from Boston University School of Medicine. Dr. Talusan completed his Orthopaedic Surgery residency at Yale University School of Medicine, where he published numerous peer-reviewed articles and received the O. Donald Chrisman Research Award. Following completion of his residency at Yale University, Dr. Talusan pursued his Foot and Ankle fellowship training at Union Memorial Hospital in Baltimore, MD. Dr. Talusan is an active member in multiple societies including the American Orthopaedic Foot and Ankle Society and the American Academy of Orthopaedic Surgeons.

James R. Holmes, MD, FAOA Associate Professor Vice Chair, Clinical Affairs Department of Orthopaedic Surgery University of Michigan Medical School Associate Chief Clinical Officer, Ortho/PMR University of Michigan Medical Group Bio: James R. Holmes is a Clinical Associate Professor of Orthopaedic Surgery at University of Michigan where he serves as Chief of the Foot and Ankle section. Prior to his current position, he spent 19 years in private practice and has been able to translate some those “lessons learned” to the academic environment. As an educator, his engagement has spanned the continuum from residency (Associate Program Director for 6 years) to fellowship (Chair of the AOFAS Fellowship Committee for 5 years) to postgraduate education (director of a large regional Foot & Ankle course for the last 20 years). Clinically, he continues to evaluate and treat a broad array foot ankle problems including complex trauma, adult reconstruction, and sports injuries.

Dr. Neary, MD Dr. Neary is a nationally recognized Board Certified Orthopaedic Surgeon that specializes in Foot and Ankle injuries and deformities, treating patients throughout the Greater Mountain West region. Dr. Neary has enabled professional athletes, weekend warriors, and all types of recreationalists to get back to their preferred level of activity, in a friendly, patient-centric atmosphere. Dr. Neary was born and raised in Tacoma, Washington. Her family was incredibly active, taking full advantage of the outdoor opportunities provided by the Pacific Northwest. This helped to foster her life-long passion for the outdoors and belief in the importance of maintaining a healthy and active lifestyle – all values that later contributed to her pursuit of a career in Orthopaedic Surgery. She excelled as a student-athlete at the University of Minnesota where she played Division 1 soccer, was recognized as an Academic All-American, and played professionally for the Minnesota Lightning. Dr. Neary then fulfilled a lifelong dream, graduating medical school from Creighton University in Omaha, Nebraska. This was followed by Orthopaedic Surgery residency at the University of Nebraska Medical Center and a Foot and Ankle fellowship at U.C. Davis/Reno Orthopaedic Clinic. She now practices as a full time Orthopaedic Foot and Ankle Surgeon in Boise, Idaho.

Christopher Miller, MD is the chief of orthopaedic foot and ankle surgery at Beth Israel Deaconess Medical Center in Boston, MA. He teaches residents and fellows as part of the Harvard Combined Orthopaedic Residency Program. He trained at Yale University School of Medicine for his residency and then completed his fellowship at Brigham and Women's Hospital. He has a particular interested in minimally invasive foot and ankle surgery.